The research-grade biosimilar is Type II humanised monoclonal antibody that targets CD20 expressed on pre- and mature B lymphocyte cells. The antibody is glycoengineered to increase the binding of CD 64 and CD16 by 7-10 folds and improve antibody-dependent cellular cytotoxicity (ADCC). Additionally, the glycoengineered structure of the antibody helps recruit immune effector cells such as polymorphonuclear neutrophils (PMNs), which when activated, release inflammatory mediators, and promote phagocytosis. A previous study demonstrated that the binding of the antibody to CD20 causes rearrangement of the actin cytoskeleton, which causes the lysosomal compartment to expand. As a result, the lysosomal membrane becomes permeable, causing Cathepsin B to leak into the cytosol. Excessive leakage of Cathepsin B promotes cell death by necrosis. The original drug has been approved by the FDA to treat patients with chronic lymphocytic leukemia (CLL) in combination with Chlorambucil.
In PBS, pH 7.5